Cargando…

New Pharmacological Approaches for the Treatment of Neurotrophic Keratitis

Neurotrophic keratitis (NK) is a rare degenerative condition that is caused by damage to the trigeminal nerve, with partial or complete loss of corneal sensory innervation. The loss of innervation leads to impaired healing of corneal epithelium, which subsequently results in punctate epithelial eros...

Descripción completa

Detalles Bibliográficos
Autores principales: Koay, Su Yin, Larkin, Daniel F. P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8981034/
https://www.ncbi.nlm.nih.gov/pubmed/35392574
http://dx.doi.org/10.3389/fphar.2022.796854
_version_ 1784681518389526528
author Koay, Su Yin
Larkin, Daniel F. P.
author_facet Koay, Su Yin
Larkin, Daniel F. P.
author_sort Koay, Su Yin
collection PubMed
description Neurotrophic keratitis (NK) is a rare degenerative condition that is caused by damage to the trigeminal nerve, with partial or complete loss of corneal sensory innervation. The loss of innervation leads to impaired healing of corneal epithelium, which subsequently results in punctate epithelial erosions, persistent epithelial defects, corneal ulcers and corneal perforation. Management of NK is often supportive and aims to promote epithelial healing and prevent progression of disease. Multiple novel pharmacological approaches have been proposed to address the underlying pathophysiology of NK, which are discussed in this paper.
format Online
Article
Text
id pubmed-8981034
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-89810342022-04-06 New Pharmacological Approaches for the Treatment of Neurotrophic Keratitis Koay, Su Yin Larkin, Daniel F. P. Front Pharmacol Pharmacology Neurotrophic keratitis (NK) is a rare degenerative condition that is caused by damage to the trigeminal nerve, with partial or complete loss of corneal sensory innervation. The loss of innervation leads to impaired healing of corneal epithelium, which subsequently results in punctate epithelial erosions, persistent epithelial defects, corneal ulcers and corneal perforation. Management of NK is often supportive and aims to promote epithelial healing and prevent progression of disease. Multiple novel pharmacological approaches have been proposed to address the underlying pathophysiology of NK, which are discussed in this paper. Frontiers Media S.A. 2022-03-22 /pmc/articles/PMC8981034/ /pubmed/35392574 http://dx.doi.org/10.3389/fphar.2022.796854 Text en Copyright © 2022 Koay and Larkin. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Koay, Su Yin
Larkin, Daniel F. P.
New Pharmacological Approaches for the Treatment of Neurotrophic Keratitis
title New Pharmacological Approaches for the Treatment of Neurotrophic Keratitis
title_full New Pharmacological Approaches for the Treatment of Neurotrophic Keratitis
title_fullStr New Pharmacological Approaches for the Treatment of Neurotrophic Keratitis
title_full_unstemmed New Pharmacological Approaches for the Treatment of Neurotrophic Keratitis
title_short New Pharmacological Approaches for the Treatment of Neurotrophic Keratitis
title_sort new pharmacological approaches for the treatment of neurotrophic keratitis
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8981034/
https://www.ncbi.nlm.nih.gov/pubmed/35392574
http://dx.doi.org/10.3389/fphar.2022.796854
work_keys_str_mv AT koaysuyin newpharmacologicalapproachesforthetreatmentofneurotrophickeratitis
AT larkindanielfp newpharmacologicalapproachesforthetreatmentofneurotrophickeratitis